

117TH CONGRESS
2D SESSION

H. R. 6625

To prohibit the Secretary of Health and Human Services from issuing guidance intended to restrict access to COVID–19 monoclonal antibody therapies and other treatments.

IN THE HOUSE OF REPRESENTATIVES

FEBRUARY 7, 2022

Mr. RODNEY DAVIS of Illinois (for himself, Ms. MALLIOTAKIS, Mr. GARBARINO, Mr. GRAVES of Missouri, Ms. VAN DUYN, Mr. FEENSTRA, Mr. LAMBORN, Mrs. CAMMACK, Mr. BOST, and Ms. TENNEY) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To prohibit the Secretary of Health and Human Services from issuing guidance intended to restrict access to COVID–19 monoclonal antibody therapies and other treatments.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Equal Access to Thera-
5 peutics Act”.

1 **SEC. 2. PROHIBITION ON RESTRICTIONS ON DIRECT AC-**
2 **CESS TO COVID-19 MONOCLONAL ANTIBODY**
3 **THERAPIES.**

4 (a) IN GENERAL.—Notwithstanding any other provi-
5 sion of law, the Secretary of Health and Human Services
6 may not issue, implement, or continue in effect any policy
7 or guidance intended to base any determination on wheth-
8 er an individual may access COVID-19 monoclonal anti-
9 body therapies and other COVID-19 treatments on the
10 race or ethnicity of such individual.

11 (b) PENALTIES.—The Secretary of Health and
12 Human Services shall be held personally liable for the
13 death of any individual who is denied access to COVID-
14 19 monoclonal antibody therapies and other treatments
15 pursuant to any policy or guidance prohibited under sub-
16 section (a).

17 **SEC. 3. PROHIBITION ON FEDERAL FUNDING TO HOS-**
18 **PITALS AND HEALTH CARE PROVIDERS WHO**
19 **RESTRICT ACCESS TO COVID-19**
20 **MONOCLONAL ANTIBODY THERAPIES.**

21 No Federal funds may be disbursed to any hospital
22 or other health care provider that has in effect a policy
23 that restricts access by individuals to COVID-19
24 monoclonal antibody therapies and other COVID-19

- 1 treatments based on the race or ethnicity of such individ-
- 2 uals.

